67 related articles for article (PubMed ID: 15739201)
1. Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro.
Hashimoto K; Morishige K; Sawada K; Tahara M; Shimizu S; Sakata M; Tasaka K; Murata Y
Cancer; 2005 Apr; 103(7):1529-36. PubMed ID: 15739201
[TBL] [Abstract][Full Text] [Related]
2. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho.
Sawada K; Morishige K; Tahara M; Kawagishi R; Ikebuchi Y; Tasaka K; Murata Y
Cancer Res; 2002 Nov; 62(21):6015-20. PubMed ID: 12414621
[TBL] [Abstract][Full Text] [Related]
3. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
Ogata S; Morishige K; Sawada K; Hashimoto K; Mabuchi S; Kawase C; Ooyagi C; Sakata M; Kimura T
Int J Gynecol Cancer; 2009 Dec; 19(9):1473-80. PubMed ID: 19955921
[TBL] [Abstract][Full Text] [Related]
4. Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo.
Hashimoto K; Morishige K; Sawada K; Ogata S; Tahara M; Shimizu S; Sakata M; Tasaka K; Kimura T
Biochem Biophys Res Commun; 2007 Apr; 356(1):72-7. PubMed ID: 17343825
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells.
Sawada K; Morishige Ki; Tahara M; Ikebuchi Y; Kawagishi R; Tasaka K; Murata Y
Gynecol Oncol; 2002 Dec; 87(3):252-9. PubMed ID: 12468322
[TBL] [Abstract][Full Text] [Related]
6. Geranylgeranylacetone blocks doxorubicin-induced cardiac toxicity and reduces cancer cell growth and invasion through RHO pathway inhibition.
Sysa-Shah P; Xu Y; Guo X; Pin S; Bedja D; Bartock R; Tsao A; Hsieh A; Wolin MS; Moens A; Raman V; Orita H; Gabrielson KL
Mol Cancer Ther; 2014 Jul; 13(7):1717-28. PubMed ID: 24737026
[TBL] [Abstract][Full Text] [Related]
7. rho-Mediated protein tyrosine phosphorylation in lysophosphatidic-acid-induced tumor-cell invasion.
Imamura F; Shinkai K; Mukai M; Yoshioka K; Komagome R; Iwasaki T; Akedo H
Int J Cancer; 1996 Mar; 65(5):627-32. PubMed ID: 8598314
[TBL] [Abstract][Full Text] [Related]
8. Isoprenoid geranylgeranylacetone inhibits human colon cancer cells through induction of apoptosis and cell cycle arrest.
Yoshikawa N; Tsuno NH; Okaji Y; Kawai K; Shuno Y; Nagawa H; Oshima N; Takahashi K
Anticancer Drugs; 2010 Oct; 21(9):850-60. PubMed ID: 20724917
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of focal adhesion kinase and paxillin phosphorylation by the small GTP-binding protein Rho in human corneal epithelial cells.
Saito J; Morishige N; Chikama T; Gu J; Sekiguchi K; Nishida T
Jpn J Ophthalmol; 2004; 48(3):199-207. PubMed ID: 15175910
[TBL] [Abstract][Full Text] [Related]
10. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling.
Zhong WB; Liang YC; Wang CY; Chang TC; Lee WS
Endocr Relat Cancer; 2005 Sep; 12(3):615-29. PubMed ID: 16172195
[TBL] [Abstract][Full Text] [Related]
11. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
So J; Wang FQ; Navari J; Schreher J; Fishman DA
Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase A inhibits lysophosphatidic acid induction of serum response factor via alterations in the actin cytoskeleton.
Nguyen GH; French R; Radhakrishna H
Cell Signal; 2004 Oct; 16(10):1141-51. PubMed ID: 15240009
[TBL] [Abstract][Full Text] [Related]
13. S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells.
Smicun Y; Gil O; Devine K; Fishman DA
Gynecol Oncol; 2007 Nov; 107(2):298-309. PubMed ID: 17716713
[TBL] [Abstract][Full Text] [Related]
14. Lovastatin-induced cytoskeletal reorganization in lens epithelial cells: role of Rho GTPases.
Maddala RL; Reddy VN; Rao PV
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2610-5. PubMed ID: 11581207
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion.
Wang FQ; Smicun Y; Calluzzo N; Fishman DA
Mol Cancer Res; 2006 Nov; 4(11):831-41. PubMed ID: 17114341
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Nakamura H
Cancer Res; 2001 Jun; 61(12):4885-91. PubMed ID: 11406567
[TBL] [Abstract][Full Text] [Related]
17. Sequential activation of RhoA and FAK/paxillin leads to ATP release and actin reorganization in human endothelium.
Hirakawa M; Oike M; Karashima Y; Ito Y
J Physiol; 2004 Jul; 558(Pt 2):479-88. PubMed ID: 15155793
[TBL] [Abstract][Full Text] [Related]
18. Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate.
Wang F; Nohara K; Olivera A; Thompson EW; Spiegel S
Exp Cell Res; 1999 Feb; 247(1):17-28. PubMed ID: 10047444
[TBL] [Abstract][Full Text] [Related]
19. Regulation of astrocyte morphology by RhoA and lysophosphatidic acid.
Ramakers GJ; Moolenaar WH
Exp Cell Res; 1998 Dec; 245(2):252-62. PubMed ID: 9851865
[TBL] [Abstract][Full Text] [Related]
20. Y-27632, an inhibitor of Rho-associated kinases, prevents tyrosine phosphorylation of focal adhesion kinase and paxillin induced by bombesin: dissociation from tyrosine phosphorylation of p130(CAS).
Sinnett-Smith J; Lunn JA; Leopoldt D; Rozengurt E
Exp Cell Res; 2001 Jun; 266(2):292-302. PubMed ID: 11399057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
